Share Price and Basic Stock Data
Last Updated: October 22, 2025, 5:18 am
| PEG Ratio | -6.93 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Vaishali Pharma Ltd operates in the pharmaceutical sector, reporting a current market capitalization of ₹119 Cr. Over the recent quarters, the company has displayed fluctuating sales trends, with revenues reaching ₹32.40 Cr in the March 2024 quarter, up from ₹26.24 Cr in March 2023. However, the latest figures indicate a drop to ₹18.08 Cr in June 2024, suggesting volatility in revenue generation. The total sales for the trailing twelve months stood at ₹99.03 Cr as of March 2025, showing an increase from ₹86.28 Cr in March 2024. This growth trajectory highlights the company’s resilience despite challenges in maintaining consistent quarterly performance. Operating Profit Margins (OPM) have also fluctuated, recording a low of 2.97% in March 2023 but recovering to 5.77% in June 2025. The company’s ability to navigate market dynamics effectively will be crucial for sustaining revenue growth moving forward.
Profitability and Efficiency Metrics
In terms of profitability, Vaishali Pharma reported a net profit of ₹0.82 Cr for the year ending March 2025, a slight increase from ₹0.72 Cr in March 2024. The net profit margin remained relatively stable at 0.82%, indicating that while profitability is present, it is constrained by high operational costs. The Return on Equity (ROE) is at a modest 1.52%, and the Return on Capital Employed (ROCE) stands at 4.93%, both figures suggesting that the company is not maximizing shareholder value effectively compared to industry standards. The Interest Coverage Ratio (ICR) is reported at 2.08x, which reflects a manageable level of debt servicing capability, although this is on the lower end of the spectrum for healthy companies. The Cash Conversion Cycle (CCC) of 77 days indicates that the company takes a long time to convert its investments into cash, highlighting potential inefficiencies in inventory management and receivables collection.
Balance Sheet Strength and Financial Ratios
Vaishali Pharma’s balance sheet reflects a cautious approach to leverage, with total borrowings reported at ₹12 Cr against reserves of ₹39 Cr, resulting in a Debt/Equity ratio of 0.17. This low ratio suggests a conservative capital structure, which may provide stability in turbulent market conditions. The company’s current ratio stands at 2.61, indicating strong liquidity, as it has more than twice the current assets to cover its current liabilities. However, the Price to Book Value (P/BV) ratio of 2.53x could be perceived as high, which may deter value-oriented investors. The company has shown a consistent trend in increasing its reserves over the years, from ₹3 Cr in March 2014 to ₹39 Cr in March 2025, which is a positive indicator of retained earnings and potential reinvestment in growth opportunities. Nevertheless, the low profitability metrics raise concerns about the effective utilization of these reserves.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Vaishali Pharma indicates a significant public ownership of 73.68%, while promoters hold 26.32%. Notably, there are no Foreign Institutional Investors (FIIs) involved, which may reflect a lack of confidence or interest from large institutional players. The number of shareholders has seen a substantial increase, climbing from 8,347 in September 2022 to 28,682 in March 2025, indicating growing retail interest. This trend could be a positive signal for market sentiment; however, the absence of FIIs may suggest caution regarding the company’s growth prospects. The stability in promoter holding percentages over time may instill some confidence among investors, but the company’s P/E ratio of 296 raises eyebrows regarding valuation, suggesting that investors may be pricing in high growth that has not yet materialized.
Outlook, Risks, and Final Insight
If margins sustain and operational efficiencies improve, Vaishali Pharma has the potential to enhance its profitability metrics significantly. However, the company faces risks such as fluctuating sales due to market volatility and pressure on profit margins from rising operational costs. Additionally, the lack of institutional support and a high P/E ratio could pose challenges in attracting broader investor interest. The management’s ability to streamline operations and manage working capital effectively will be crucial in navigating these challenges. If the company can leverage its growing reserves for strategic investments, it may position itself for a more stable growth trajectory. Overall, while there are promising signs in terms of revenue growth and shareholder interest, the company must address its profitability and efficiency issues to realize its full potential.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Vaishali Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 137 Cr. | 35.6 | 869/31.9 | 1.33 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 2,498 Cr. | 183 | 227/124 | 101 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 55.8 Cr. | 4.37 | 8.90/3.97 | 5.12 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,548.39 Cr | 262.10 | 348.45 | 100.76 | 0.22% | 11.73% | 22.92% | 9.18 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.18 | 13.16 | 20.09 | 26.24 | 13.42 | 12.57 | 27.90 | 32.40 | 18.08 | 20.79 | 27.91 | 32.25 | 23.75 |
| Expenses | 7.98 | 10.57 | 16.53 | 25.46 | 11.11 | 9.92 | 24.95 | 39.19 | 15.73 | 18.37 | 26.55 | 38.29 | 22.38 |
| Operating Profit | 2.20 | 2.59 | 3.56 | 0.78 | 2.31 | 2.65 | 2.95 | -6.79 | 2.35 | 2.42 | 1.36 | -6.04 | 1.37 |
| OPM % | 21.61% | 19.68% | 17.72% | 2.97% | 17.21% | 21.08% | 10.57% | -20.96% | 13.00% | 11.64% | 4.87% | -18.73% | 5.77% |
| Other Income | 0.43 | 0.74 | 0.53 | 0.53 | 0.36 | 0.30 | 0.47 | 0.91 | 0.42 | 0.71 | 1.07 | 1.00 | 0.84 |
| Interest | 0.53 | 0.53 | 0.42 | 0.54 | 0.43 | 0.47 | 0.43 | 0.40 | 0.38 | 0.38 | 0.38 | 0.44 | 0.33 |
| Depreciation | 0.09 | 0.14 | 0.12 | 0.15 | 0.12 | 0.12 | 0.12 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.14 |
| Profit before tax | 2.01 | 2.66 | 3.55 | 0.62 | 2.12 | 2.36 | 2.87 | -6.42 | 2.27 | 2.63 | 1.93 | -5.60 | 1.74 |
| Tax % | 24.88% | 24.81% | 25.07% | 29.03% | 25.00% | 27.97% | 26.13% | -26.95% | 25.11% | 25.10% | 24.87% | -23.39% | 26.44% |
| Net Profit | 1.51 | 1.99 | 2.66 | 0.44 | 1.59 | 1.70 | 2.11 | -4.68 | 1.70 | 1.97 | 1.44 | -4.29 | 1.28 |
| EPS in Rs | 0.14 | 0.19 | 0.25 | 0.04 | 0.15 | 0.16 | 0.20 | -0.44 | 0.16 | 0.18 | 0.13 | -0.40 | 0.12 |
Last Updated: August 20, 2025, 1:35 am
Below is a detailed analysis of the quarterly data for Vaishali Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 23.75 Cr.. The value appears to be declining and may need further review. It has decreased from 32.25 Cr. (Mar 2025) to 23.75 Cr., marking a decrease of 8.50 Cr..
- For Expenses, as of Jun 2025, the value is 22.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.29 Cr. (Mar 2025) to 22.38 Cr., marking a decrease of 15.91 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.37 Cr.. The value appears strong and on an upward trend. It has increased from -6.04 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 7.41 Cr..
- For OPM %, as of Jun 2025, the value is 5.77%. The value appears strong and on an upward trend. It has increased from -18.73% (Mar 2025) to 5.77%, marking an increase of 24.50%.
- For Other Income, as of Jun 2025, the value is 0.84 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2025) to 0.84 Cr., marking a decrease of 0.16 Cr..
- For Interest, as of Jun 2025, the value is 0.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.44 Cr. (Mar 2025) to 0.33 Cr., marking a decrease of 0.11 Cr..
- For Depreciation, as of Jun 2025, the value is 0.14 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.12 Cr. (Mar 2025) to 0.14 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.74 Cr.. The value appears strong and on an upward trend. It has increased from -5.60 Cr. (Mar 2025) to 1.74 Cr., marking an increase of 7.34 Cr..
- For Tax %, as of Jun 2025, the value is 26.44%. The value appears to be increasing, which may not be favorable. It has increased from -23.39% (Mar 2025) to 26.44%, marking an increase of 49.83%.
- For Net Profit, as of Jun 2025, the value is 1.28 Cr.. The value appears strong and on an upward trend. It has increased from -4.29 Cr. (Mar 2025) to 1.28 Cr., marking an increase of 5.57 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.12. The value appears strong and on an upward trend. It has increased from -0.40 (Mar 2025) to 0.12, marking an increase of 0.52.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 95 | 67 | 64 | 68 | 75 | 60 | 54 | 76 | 70 | 86 | 99 | 105 |
| Expenses | 118 | 95 | 66 | 60 | 65 | 73 | 59 | 51 | 69 | 60 | 85 | 98 | 106 |
| Operating Profit | 2 | -0 | 1 | 3 | 3 | 2 | 1 | 3 | 7 | 9 | 2 | 1 | -1 |
| OPM % | 2% | -0% | 1% | 5% | 4% | 3% | 2% | 5% | 9% | 13% | 2% | 1% | -1% |
| Other Income | 1 | 4 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit before tax | 1 | 0 | -0 | 1 | 1 | 1 | 0 | 1 | 6 | 9 | 1 | 1 | 1 |
| Tax % | 50% | -7% | 300% | 32% | 41% | 37% | 62% | 26% | 30% | 25% | 23% | 34% | |
| Net Profit | 0 | 0 | -0 | 1 | 1 | 1 | 0 | 1 | 4 | 7 | 1 | 1 | 0 |
| EPS in Rs | 0.38 | 0.20 | -0.04 | 0.15 | 0.08 | 0.07 | 0.00 | 0.10 | 0.38 | 0.63 | 0.07 | 0.08 | 0.03 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | -100.00% | 300.00% | 75.00% | -85.71% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | -100.00% | 400.00% | -225.00% | -160.71% | 85.71% |
Vaishali Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 94% |
| 3 Years: | -41% |
| TTM: | -52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 8% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: September 10, 2025, 2:46 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.50 | 0.50 | 0.50 | 3 | 7 | 7 | 11 | 11 | 11 | 11 | 11 | 26 |
| Reserves | 3 | 3 | 3 | 1 | 14 | 15 | 11 | 12 | 16 | 30 | 32 | 39 |
| Borrowings | 19 | 25 | 21 | 23 | 18 | 17 | 17 | 18 | 21 | 15 | 13 | 12 |
| Other Liabilities | 32 | 17 | 25 | 18 | 25 | 30 | 28 | 46 | 34 | 24 | 24 | 33 |
| Total Liabilities | 53 | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 82 | 79 | 80 | 110 |
| Fixed Assets | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 53 | 44 | 48 | 43 | 62 | 67 | 64 | 84 | 80 | 76 | 77 | 107 |
| Total Assets | 53 | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 82 | 79 | 80 | 110 |
Below is a detailed analysis of the balance sheet data for Vaishali Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2024) to 26.00 Cr., marking an increase of 15.00 Cr..
- For Reserves, as of Mar 2025, the value is 39.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Mar 2024) to 39.00 Cr., marking an increase of 7.00 Cr..
- For Borrowings, as of Mar 2025, the value is 12.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.00 Cr. (Mar 2024) to 12.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 33.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 24.00 Cr. (Mar 2024) to 33.00 Cr., marking an increase of 9.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 110.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 80.00 Cr. (Mar 2024) to 110.00 Cr., marking an increase of 30.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 107.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Mar 2024) to 107.00 Cr., marking an increase of 30.00 Cr..
- For Total Assets, as of Mar 2025, the value is 110.00 Cr.. The value appears strong and on an upward trend. It has increased from 80.00 Cr. (Mar 2024) to 110.00 Cr., marking an increase of 30.00 Cr..
Notably, the Reserves (39.00 Cr.) exceed the Borrowings (12.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -17.00 | -25.00 | -20.00 | -20.00 | -15.00 | -15.00 | -16.00 | -15.00 | -14.00 | -6.00 | -11.00 | -11.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 116 | 133 | 221 | 214 | 240 | 240 | 286 | 453 | 282 | 281 | 209 | 172 |
| Inventory Days | 26 | 13 | 20 | 7 | 11 | 5 | 6 | 5 | 4 | 20 | 2 | 20 |
| Days Payable | 99 | 66 | 145 | 100 | 136 | 130 | 169 | 321 | 163 | 120 | 95 | 116 |
| Cash Conversion Cycle | 43 | 80 | 96 | 121 | 115 | 115 | 123 | 137 | 122 | 181 | 116 | 77 |
| Working Capital Days | 59 | 98 | 25 | 14 | 97 | 98 | 124 | 146 | 111 | 208 | 169 | 231 |
| ROCE % | 19% | 14% | 13% | 16% | 13% | 10% | 7% | 10% | 19% | 22% | 6% | 5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.06 | 0.68 | 6.26 | 3.82 | 0.99 |
| Diluted EPS (Rs.) | 0.06 | 0.64 | 5.91 | 3.82 | 0.99 |
| Cash EPS (Rs.) | 0.09 | 1.14 | 6.74 | 4.25 | 1.40 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 4.98 | 33.41 | 31.26 | 24.99 | 21.26 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 4.98 | 33.41 | 31.26 | 24.99 | 21.26 |
| Revenue From Operations / Share (Rs.) | 7.59 | 80.49 | 66.05 | 71.89 | 50.99 |
| PBDIT / Share (Rs.) | 0.25 | 2.96 | 10.77 | 8.20 | 4.21 |
| PBIT / Share (Rs.) | 0.21 | 2.48 | 10.29 | 7.76 | 3.81 |
| PBT / Share (Rs.) | 0.09 | 0.86 | 8.39 | 5.43 | 1.33 |
| Net Profit / Share (Rs.) | 0.06 | 0.67 | 6.26 | 3.81 | 0.99 |
| PBDIT Margin (%) | 3.32 | 3.67 | 16.30 | 11.39 | 8.26 |
| PBIT Margin (%) | 2.83 | 3.08 | 15.58 | 10.79 | 7.46 |
| PBT Margin (%) | 1.23 | 1.07 | 12.69 | 7.55 | 2.61 |
| Net Profit Margin (%) | 0.82 | 0.83 | 9.47 | 5.30 | 1.94 |
| Return on Networth / Equity (%) | 1.25 | 2.00 | 20.02 | 15.26 | 4.66 |
| Return on Capital Employeed (%) | 4.02 | 5.68 | 23.17 | 27.57 | 14.94 |
| Return On Assets (%) | 0.74 | 0.89 | 8.36 | 4.92 | 1.21 |
| Long Term Debt / Equity (X) | 0.06 | 0.10 | 0.15 | 0.11 | 0.18 |
| Total Debt / Equity (X) | 0.17 | 0.35 | 0.41 | 0.78 | 0.71 |
| Asset Turnover Ratio (%) | 1.04 | 1.09 | 0.86 | 0.90 | 0.70 |
| Current Ratio (X) | 2.61 | 2.25 | 2.27 | 1.47 | 1.37 |
| Quick Ratio (X) | 2.49 | 2.24 | 2.17 | 1.46 | 1.36 |
| Inventory Turnover Ratio (X) | 38.16 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.08 | 1.83 | 5.66 | 3.52 | 1.70 |
| Interest Coverage Ratio (Post Tax) (X) | 1.52 | 1.41 | 4.29 | 2.64 | 1.40 |
| Enterprise Value (Cr.) | 173.94 | 161.15 | 166.55 | 89.17 | 49.85 |
| EV / Net Operating Revenue (X) | 1.76 | 1.87 | 2.39 | 1.18 | 0.92 |
| EV / EBITDA (X) | 52.78 | 50.82 | 14.66 | 10.32 | 11.22 |
| MarketCap / Net Operating Revenue (X) | 1.66 | 1.74 | 2.21 | 0.92 | 0.63 |
| Price / BV (X) | 2.53 | 4.19 | 4.67 | 2.65 | 1.53 |
| Price / Net Operating Revenue (X) | 1.66 | 1.74 | 2.21 | 0.92 | 0.63 |
| EarningsYield | 0.00 | 0.00 | 0.04 | 0.05 | 0.03 |
After reviewing the key financial ratios for Vaishali Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 2.00, marking a decrease of 8.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.68 (Mar 24) to 0.06, marking a decrease of 0.62.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.64 (Mar 24) to 0.06, marking a decrease of 0.58.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 3. It has decreased from 1.14 (Mar 24) to 0.09, marking a decrease of 1.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.59. It has decreased from 80.49 (Mar 24) to 7.59, marking a decrease of 72.90.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 2. It has decreased from 2.96 (Mar 24) to 0.25, marking a decrease of 2.71.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 2.48 (Mar 24) to 0.21, marking a decrease of 2.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has decreased from 0.86 (Mar 24) to 0.09, marking a decrease of 0.77.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 2. It has decreased from 0.67 (Mar 24) to 0.06, marking a decrease of 0.61.
- For PBDIT Margin (%), as of Mar 25, the value is 3.32. This value is below the healthy minimum of 10. It has decreased from 3.67 (Mar 24) to 3.32, marking a decrease of 0.35.
- For PBIT Margin (%), as of Mar 25, the value is 2.83. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 2.83, marking a decrease of 0.25.
- For PBT Margin (%), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 10. It has increased from 1.07 (Mar 24) to 1.23, marking an increase of 0.16.
- For Net Profit Margin (%), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 5. It has decreased from 0.83 (Mar 24) to 0.82, marking a decrease of 0.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 15. It has decreased from 2.00 (Mar 24) to 1.25, marking a decrease of 0.75.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.02. This value is below the healthy minimum of 10. It has decreased from 5.68 (Mar 24) to 4.02, marking a decrease of 1.66.
- For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has decreased from 0.89 (Mar 24) to 0.74, marking a decrease of 0.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.06, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has decreased from 0.35 (Mar 24) to 0.17, marking a decrease of 0.18.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.04. It has decreased from 1.09 (Mar 24) to 1.04, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 2.25 (Mar 24) to 2.61, marking an increase of 0.36.
- For Quick Ratio (X), as of Mar 25, the value is 2.49. This value exceeds the healthy maximum of 2. It has increased from 2.24 (Mar 24) to 2.49, marking an increase of 0.25.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 38.16. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 38.16, marking an increase of 38.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.08. This value is below the healthy minimum of 3. It has increased from 1.83 (Mar 24) to 2.08, marking an increase of 0.25.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has increased from 1.41 (Mar 24) to 1.52, marking an increase of 0.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 173.94. It has increased from 161.15 (Mar 24) to 173.94, marking an increase of 12.79.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 1.87 (Mar 24) to 1.76, marking a decrease of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 52.78. This value exceeds the healthy maximum of 15. It has increased from 50.82 (Mar 24) to 52.78, marking an increase of 1.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
- For Price / BV (X), as of Mar 25, the value is 2.53. This value is within the healthy range. It has decreased from 4.19 (Mar 24) to 2.53, marking a decrease of 1.66.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vaishali Pharma Ltd:
- Net Profit Margin: 0.82%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.02% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.25% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 276 (Industry average Stock P/E: 348.45)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.82%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 706 to 709, 7th Floor, Aravali Business Center, Mumbai Maharashtra 400092 | cs@vaishalipharma.com http://www.vaishalipharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Atul Arvind Vasani | Chairman & Managing Director |
| Mr. Dewansh Ajay Vasani | Executive Director & CFO |
| Mrs. Jagruti Atul Vasani | Whole Time Director |
| Mr. Manish Bhagwandas Ved | Ind. Non-Executive Director |
| Mr. Pratik Vikram Jakhelia | Ind. Non-Executive Director |
| Mr. Bhaveshkumar Upadhyay | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Vaishali Pharma Ltd?
Vaishali Pharma Ltd's intrinsic value (as of 24 October 2025) is 20.75 which is 101.46% higher the current market price of 10.30, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 111 Cr. market cap, FY2025-2026 high/low of 20.4/9.00, reserves of ₹39 Cr, and liabilities of 110 Cr.
What is the Market Cap of Vaishali Pharma Ltd?
The Market Cap of Vaishali Pharma Ltd is 111 Cr..
What is the current Stock Price of Vaishali Pharma Ltd as on 24 October 2025?
The current stock price of Vaishali Pharma Ltd as on 24 October 2025 is 10.3.
What is the High / Low of Vaishali Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vaishali Pharma Ltd stocks is 20.4/9.00.
What is the Stock P/E of Vaishali Pharma Ltd?
The Stock P/E of Vaishali Pharma Ltd is 276.
What is the Book Value of Vaishali Pharma Ltd?
The Book Value of Vaishali Pharma Ltd is 6.06.
What is the Dividend Yield of Vaishali Pharma Ltd?
The Dividend Yield of Vaishali Pharma Ltd is 0.00 %.
What is the ROCE of Vaishali Pharma Ltd?
The ROCE of Vaishali Pharma Ltd is 4.93 %.
What is the ROE of Vaishali Pharma Ltd?
The ROE of Vaishali Pharma Ltd is 1.52 %.
What is the Face Value of Vaishali Pharma Ltd?
The Face Value of Vaishali Pharma Ltd is 2.00.